+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New Molecular Entity Drug Market - Global Forecast 2025-2030- Product Image
New Molecular Entity Drug Market - Global Forecast 2025-2030- Product Image
Sale

New Molecular Entity Drug Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6141085
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Next-generation molecular entities are reshaping the therapeutic landscape, ushering in a new era of targeted drug development and precision medicine. Built on advances in structural biology, computational chemistry, and high-throughput screening, these innovations are accelerating the creation and adoption of more effective therapies across multiple disease areas.

Market Snapshot: New Molecular Entities Market Overview

The global market for new molecular entities (NMEs) is seeing sustained growth, driven by increased investment in pipeline diversification and technological innovation. With heightened demand for precision medicine and the rising emphasis on value-based healthcare, industry leaders are forging strategic partnerships to efficiently navigate clinical development, regulatory approval, and commercialization. Companies across the pharmaceutical and biotechnology sectors are leveraging adaptive R&D frameworks and digital health integration to improve patient engagement and streamline development.

Scope & Segmentation of the New Molecular Entities Market

This market research report provides comprehensive analysis and revenue forecasts across key segments and regions, supporting strategic planning and competitive benchmarking. It dissects trends affecting NMEs by therapeutic use, molecular approach, formulation, patient group, and delivery method. Coverage includes examination of the international supply chain and assessment of major industry players.

  • Therapeutic Indication: Autoimmune Disorders, Cardiovascular Disorders (Arrhythmia, Coronary Artery Disease, Heart Failure, Hypertension), Central Nervous System Disorders, Infectious Diseases, Metabolic Disorders, Oncology (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma).
  • Route of Administration: Inhalation, Nasal, Oral, Parenteral, Topical, Transdermal.
  • Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Specialty Pharmacy.
  • Molecule Class: Biologic, Cell Therapy, Gene Therapy, Peptide, Small Molecule.
  • Age Group: Adult, Geriatric, Neonatal, Pediatric.
  • Formulation: Capsule, Cream, Injection, Solution, Tablet.
  • Regional Coverage: United States (including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio), Canada, Mexico, Brazil, Argentina, United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland, China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan.
  • Leading Companies: Pfizer Inc., Roche Holding AG, Novartis AG, Merck & Co., Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Sanofi S.A., Gilead Sciences, Inc., AstraZeneca PLC.

Key Takeaways for Senior Decision-Makers

  • Collaboration between biotechs and large pharmaceutical firms is intensifying, sharing resources to overcome clinical, manufacturing, and regulatory complexities.
  • Precision molecular design is enabling targeted modulation of disease pathways, especially in oncology, metabolic, and autoimmune indications.
  • Formulation and route of administration innovation are enhancing patient adherence and broadening the range of patient populations served.
  • Regional regulatory trends vary; adaptive trial designs and faster approval pathways are supporting faster market access in major biotech hubs.
  • Investment in digital transformation and real-world evidence analytics is becoming essential to demonstrate the value and support payer reimbursement.

Tariff Impact on U.S. Pharmaceutical Supply Chains

Recent changes to tariff policies on raw materials, active pharmaceutical ingredients, and specialized equipment have prompted manufacturers to reassess their sourcing and production models. Companies are increasingly diversifying supplier bases, investing in local capacity, and strengthening supply chain analytics to reduce risk from tariff volatility and maintain efficient R&D operations.

Methodology & Data Sources

Findings draw on in-depth interviews with industry executives and clinical experts, a comprehensive review of literature and regulatory documents, and triangulation of market data from institutional reports and clinical trial registries. Analytical frameworks include scenario planning, comparative benchmarking, and peer validation to ensure accuracy and actionable insights.

Why This Report Matters

  • Supports robust strategic planning for launching and optimizing new molecular entity pipelines by providing deep insight into therapeutic, regulatory, and regional factors.
  • Empowers commercial and R&D decision makers to benchmark against leading competitors and anticipate emerging opportunities and risks.
  • Provides a clear roadmap for enhancing operational resilience and aligning with evolving global supply chain and policy dynamics.

Conclusion

Next-generation molecular entities are redefining pharmaceutical innovation and market structure through technological progress, targeted design, and new models of collaboration. This report equips leaders with the knowledge to navigate change and sustain innovation in a dynamic, competitive landscape.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising investment in AI-driven drug discovery pipelines enabling faster target identification and molecule optimization
5.2. Expansion of precision medicine initiatives leveraging genomic data to tailor new molecular entity therapies to patient subpopulations
5.3. Regulatory acceleration programs like FDA’s breakthrough therapy designation reducing time to market for innovative NMEs
5.4. Strategic partnerships between biotech startups and big pharma to co-develop next-generation molecular entities addressing rare diseases
5.5. Growing focus on bispecific and multispecific molecules to enhance therapeutic efficacy in oncology and autoimmune conditions
5.6. Increased adoption of mRNA platform technologies for rapid development of novel molecular entity vaccines and therapeutics
5.7. Implementation of advanced bioinformatics and machine learning for predictive ADMET profiling in early NME development stages
5.8. Surge in global clinical trial outsourcing to contract research organizations for early-phase testing of NMEs
5.9. Emphasis on sustainability and green chemistry in NME synthesis to reduce environmental impact of pharmaceutical manufacturing
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. New Molecular Entity Drug Market, by Therapeutic Indication
8.1. Introduction
8.2. Autoimmune Disorders
8.3. Cardiovascular Disorders
8.3.1. Arrhythmia
8.3.2. Coronary Artery Disease
8.3.3. Heart Failure
8.3.4. Hypertension
8.4. Central Nervous System Disorders
8.5. Infectious Diseases
8.6. Metabolic Disorders
8.7. Oncology
8.7.1. Breast Cancer
8.7.2. Colorectal Cancer
8.7.3. Leukemia
8.7.4. Lung Cancer
8.7.5. Lymphoma
9. New Molecular Entity Drug Market, by Route Of Administration
9.1. Introduction
9.2. Inhalation
9.3. Nasal
9.4. Oral
9.5. Parenteral
9.6. Topical
9.7. Transdermal
10. New Molecular Entity Drug Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
10.5. Specialty Pharmacy
11. New Molecular Entity Drug Market, by Molecule Class
11.1. Introduction
11.2. Biologic
11.3. Cell Therapy
11.4. Gene Therapy
11.5. Peptide
11.6. Small Molecule
12. New Molecular Entity Drug Market, by Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Neonatal
12.5. Pediatric
13. New Molecular Entity Drug Market, by Formulation
13.1. Introduction
13.2. Capsule
13.3. Cream
13.4. Injection
13.5. Solution
13.6. Tablet
14. Americas New Molecular Entity Drug Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa New Molecular Entity Drug Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific New Molecular Entity Drug Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. Roche Holding AG
17.3.3. Novartis AG
17.3.4. Merck & Co., Inc.
17.3.5. Johnson & Johnson
17.3.6. AbbVie Inc.
17.3.7. Bristol-Myers Squibb Company
17.3.8. Sanofi S.A.
17.3.9. Gilead Sciences, Inc.
17.3.10. AstraZeneca PLC
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. NEW MOLECULAR ENTITY DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NEW MOLECULAR ENTITY DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NEW MOLECULAR ENTITY DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. NEW MOLECULAR ENTITY DRUG MARKET: RESEARCHAI
FIGURE 28. NEW MOLECULAR ENTITY DRUG MARKET: RESEARCHSTATISTICS
FIGURE 29. NEW MOLECULAR ENTITY DRUG MARKET: RESEARCHCONTACTS
FIGURE 30. NEW MOLECULAR ENTITY DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NEW MOLECULAR ENTITY DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY HYPERTENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY NASAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY BIOLOGIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY PEPTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY NEONATAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY NEONATAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CREAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 139. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 140. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 141. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 142. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 143. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 144. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 145. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 150. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 151. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 152. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 153. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 154. CANADA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 155. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 156. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 157. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 158. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 159. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 160. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 161. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 166. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 167. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 168. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 169. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 170. MEXICO NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 237. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 238. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 239. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 240. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 241. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 242. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 243. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 248. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 249. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 250. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 251. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 252. GERMANY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 253. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 254. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 255. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 256. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 257. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 258. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 259. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 264. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 265. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 266. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 267. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 268. FRANCE NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 285. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 286. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 287. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 288. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 289. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 290. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 291. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 296. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 297. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 298. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 299. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 300. ITALY NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 301. SPAIN NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 302. SPAIN NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 303. SPAIN NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 304. SPAIN NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 305. SPAIN NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 306. SPAIN NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 307. SPAIN NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 308. SPAIN NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 309. SPAIN NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. SPAIN NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. SPAIN NEW MOLECULAR ENTITY DRUG MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (US

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this New Molecular Entity Drug market report include:
  • Pfizer Inc.
  • Roche Holding AG
  • Novartis AG
  • Merck & Co., Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Sanofi S.A.
  • Gilead Sciences, Inc.
  • AstraZeneca PLC

Related Reports

Lysine Specific Demethylase 1 Inhibitor Market - Global Forecast to 2030 - Product Image

Lysine Specific Demethylase 1 Inhibitor Market - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Kallikrein Inhibitors Market - Global Forecast 2025-2030 - Product Image

Kallikrein Inhibitors Market - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Molecular Switches As Therapeutic Targets, Drug Development, Drug Delivery Mechanism & Application By Indications Insight 2025 - Product Image

Molecular Switches As Therapeutic Targets, Drug Development, Drug Delivery Mechanism & Application By Indications Insight 2025

  • Report
  • 150 Pages
  • Global
From
Colorectal Cancer - Pipeline Insight, 2025 - Product Image

Colorectal Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • 550 Pages
  • Global
From
Small Molecule Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow (Target Identification & Screening, Preclinical Development), By Service, By Therapeutics Area, By End Use, By Region, And Segment Forecasts, 2025 - 2033 - Product Image

Small Molecule Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow (Target Identification & Screening, Preclinical Development), By Service, By Therapeutics Area, By End Use, By Region, And Segment Forecasts, 2025 - 2033

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.